| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 1.2K | 1.1% |
| Total Income | 1.2K | 2.3% |
| Expenditure | 1.1K | 2.3% |
| PBT | 144.53 | 26.8% |
| Net Profit | 112.64 | 25.9% |
| OPM | 18.25% | 5.39pp |
| NPM | 9.18% | 3.50pp |
| EPS | 4.64 | 26.0% |
Granules India Q1FY26 Revenue Up 3%, Net Profit Down 16% YoY
12 Aug 2025 · 12 Aug 2025, 01:09 pm
Summary
Granules India Ltd., a vertically integrated pharmaceutical company, announced its financial results for the quarter ended June 30, 2025. The company's revenue from operations stood at INR 12,101 Mn, a growth of 3% YoY. However, the net profit was down by 16% YoY. The financial summary includes EBITDA before exceptional items at INR 2,467 Mn, PBT before exceptional items at INR 1,704 Mn, and PAT at INR 1,126 Mn.
Key Highlights
- 1
Q1FY26 Revenue from operations at INR 12,101 Mn up 3% YoY
- 2
EBITDA (before exceptional items) at INR 2,467 Mn down 5% YoY
- 3
PBT (before exceptional items) at INR 1,704 Mn down 6% YoY
- 4
PAT (after exceptional items) at INR 1,126 Mn down 16% YoY
- 5
Sales growth was largely driven by North America
- 6
ROCE is at 16.0% (Post Acquisition of Senn Chemicals AG) as compared to 16.6% YoY
- 7
Net debt stood at INR 9,480 Mn and Net debt to EBITDA at 0.96x
Management Comments
Dr. Krishna Prasad Chigurupati
We delivered healthy cash flow from operations of 2,806 million this quarter and made good progress on the Gagillapur remediation program. USFDA audits at our Bonthapally API facility, GPI in Virginia, and Granules Life Sciences at Genome Valley were successfully completed with one minor observation each. The Danish Medicines Agency also concluded its EU GMP inspection of Gagillapur with certification granted. With our near-term formulations growth trajectory set to resume, and the integration of Senn Chemicals through the Ascelis platform in the fast-growing CDMO sector, we are well-positioned for sustainable long-term growth
Informational and educational content only. Not investment advice.